Navigation Links
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Date:11/16/2007

versus placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), headache (7% vs 5%), and orthostatic hypotension (7% vs 5%).

In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose Greater Than or Equal To 126 mg/dl) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs 4.6% in patients receiving placebo (mean exposure 152 days).

Please see Prescribing Information, including Boxed Warnings, for SEROQUEL and SEROQUEL XR.

About Schizophrenia

Schizophrenia is a serious brain disorder with symptoms including distorted perceptions of reality, hallucinations and delusions, illogical thinking, and flat or blunted emotions.(4) Schizophrenia affects men and women with equal frequency, but the first signs of schizophrenia typically emerge earlier in men (in late teens or early twenties) compared to women (in twenties or early thirties). Approximately 2.4 million American adults -- about 1.1 % of the population age 18 and older -- suffer from schizophrenia.(5) Medications are important in the management of symptoms. While there is no cure for schizophrenia, it is a highly treatable and manageable illness. Medications are classified into two categories -- "conventional" and "atypical" antipsychotics.(7)

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZen
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... According to a new market ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... of 10.1% from 2014 to 2020. Biological ... used in the treatment and prevention of various diseases ... medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... 1, 2014 Research and Markets ... Minimally-Invasive Biomarkers in Alzheimer,s Disease: A Comprehensive Analysis and ... report to their offering. This report ... developments relating to early-stage minimally-invasive biomarkers in Alzheimer,s disease, ... and candidates in the AD drug pipeline, and applicable ...
Breaking Medicine Technology:CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 3CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 4CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 5CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 6Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2
... ANX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company,s product candidate ANX-530 (vinorelbine injectable emulsion). , ... , ... ... ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) a biotechnology company focused on the development of small-molecule ... fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance ... ... , ...
Cached Medicine Technology:ADVENTRX Receives Brand Name Acceptance for ANX-530 2ADVENTRX Receives Brand Name Acceptance for ANX-530 3ADVENTRX Receives Brand Name Acceptance for ANX-530 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 2Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 3Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 5Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 6Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 7Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 8Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 9Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 10Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 11
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many ... of employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, ... to 10% off, on these useful items. , ... 20 different kinds of high end monitoring programs on ... companies of all sizes. With its high end programs, ...
(Date:9/2/2014)... A simple awareness campaign in general practice identifies new ... at ESC Congress today by Professor Jean-Marc Davy from ... the most common cardiac arrhythmia. It multiplies the risk ... of stroke risk by five-fold. Similarly, AF is responsible ... AF is often overlooked and diagnosed too late. In ...
(Date:9/2/2014)... Developers and plugin specialist of Final Cut ... from Pixel Film Studios. , “ProIntro has enabled users ... Christina Austin, CEO of Pixel Film Studios. “Blurring the ... game changer.” , Learn how to create a title ... Studios. ProIntro is a package of professionally designed titles ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 ... for about a decade, primarily to help people ... time, there are three developed systems,” says Dana ... approaches substantively differ, the goals are much the ... support of some type of harmonica.” , The ...
(Date:9/2/2014)... AURO the enterprise Canadian Public ... expansion of its leadership team with the appointment of ... Liang joins AURO in conjunction with his current role ... with the operations, product management and engineering teams to ... well as ensuring effective internal and external controls are ...
Breaking Medicine News(10 mins):Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3
... new study finds that, despite efforts in the last ... significantly less likely than white patients to receive therapy ... study conclude that efforts to close treatment gaps initiated ... The report appears in the February 15, 2008 issue ...
... Conn., Jan. 6 Therap Services, the leading,provider ... has announced the promotion of Allison Dudo to ... responsibility of,providing help and technical guidance to users ... key part of our success, and we were ...
... heavily than male peers, field study finds , , SUNDAY, ... of college drinking behavior shows that parties with drinking ... parties encourage college women to drink more heavily than ... drinking have relied largely on individual behavior and self-reports ...
... Year,s,resolution is to lose weight, calcium and dairy can help, ... Science Hawley,Almstedt and her student Alexandra Hybki. The everyday nutrients ... down this year., People on fad diets or extreme ... foods are high in fat. Some dieters go,so far as ...
... Holdings, Inc. President Robert Oswald provides a shareholder,update., ... as we opened 5 new,locations across Canada, including the ... were fortunate to have our Official Spokesperson,for Canada, Mr. ... opening,events for our new locations. I was very pleased ...
... radiation after early-stage disease is removed, researchers say , FRIDAY, ... have not yet spread contain cells with a predisposition to ... just because a cancer has not yet spread doesn,t mean ... warned researchers at the Salk Institute for Biological Studies in ...
Cached Medicine News:Health News:Racial disparities persist in cancer care 2Health News:Therap Services Promotes Allison Dudo to Assistant Director of Training 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:Milk Does a Body and a Waistline Good 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 3Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 4Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 5Health News:Localized Breast Cancer Cells Have Potential to Spread 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: